Towards the Translation of Synergistic Phage-Polymyxin Combination Therapy against Pandrug-resistant Klebsiella pneumoniae: A Systems Approach
针对泛耐药肺炎克雷伯菌的协同噬菌体-多粘菌素联合疗法的转化:系统方法
基本信息
- 批准号:10470088
- 负责人:
- 金额:$ 13.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-16 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAmino AcidsAnimalsAntibiotic ResistanceAntibiotic TherapyAntibioticsAntimicrobial ResistanceAttentionBacteriaBacterial InfectionsBacteriophagesBiologyCellsCitratesClinicClinicalClinical TrialsCombined AntibioticsCombined Modality TherapyComplexCritical IllnessCytolysisDangerousnessDiagnosticDoseDrug KineticsFutureHealthHumanImmuneImmune responseImmunocompromised HostIn VitroInfectionInnovative TherapyKlebsiella pneumoniaeKnowledgeLifeLiteratureLyticMediatingMedicalMembrane LipidsMetabolismModelingMulti-Drug ResistanceMultiomic DataMusNational Institute of Allergy and Infectious DiseaseNucleotidesOutcomePatientsPentosephosphate PathwayPharmacodynamicsPharmacologyPlasmidsPlayPolymyxin BPolymyxin ResistancePolymyxinsRegimenReportingResearchResistanceResistance developmentResortRoleSafetySecuritySiteSpecificitySuperbugSystemTherapeuticTimeToxic effectTranslationsVirusWorld Health Organizationbacterial metabolismbacterial resistancecarbapenem resistancecombatdosageglobal healthin vivoinnovationmetabolomicsmultidisciplinarymultiple omicsnovelnovel therapeuticspathogenpriority pathogenprogramsrational designresistance mechanismresistant Klebsiella pneumoniaesynergismvirtual
项目摘要
Antimicrobial resistance (AMR) has become one of the greatest global threats to human health. Pandrug-
resistant (PDR) Klebsiella pneumoniae has been identified by the World Health Organization as one of the 3 top-
priority pathogens urgently requiring new treatments. Polymyxins are often used as the last option; however,
plasmid-mediated polymyxin resistance highlights the urgency to develop novel therapeutics to treat PDR K.
pneumoniae. Bacteriophage (i.e. phage) has recently attracted substantial attention as a promising option to
treat PDR bacterial infections; unfortunately, resistance to phage monotherapy in K. pneumoniae can rapidly
develop. Optimal phage-antibiotic combinations provide a superior approach; however, there is a significant lack
of knowledge on the pharmacokinetics/pharmacodynamics/toxicodynamics (PK/PD/TD) of phage therapy. This
situation has severely hindered the optimization of phage therapy against bacterial ‘superbugs’ and limited their
clinical utility. Traditional PK/PD/TD plays a critical role in optimizing antibiotic dosage regimens, but lacks
systems and mechanistic information. Furthermore, antibiotic PK/PD/TD cannot be easily extrapolated to phage
therapy, mainly due to their unique PK, host specificity and self-amplification. As phage-antibiotic synergy also
depends on the dynamics of infection and host responses, innovative strategies incorporating systems
pharmacology and host-pathogen-phage-antibiotic interactions have the significant potential to optimize their
clinical use. Excitingly, we have isolated a number of phages with superior activity against PDR K. pneumoniae,
and identified several novel phage-antibiotic combinations (e.g. with polymyxins) that synergistically kill PDR K.
pneumoniae in vitro and in animals without any regrowth. Considering the urgent need to optimize phage therapy
and minimize resistance to the last-line polymyxins, it is essential to develop superior phage-polymyxin
combinations using a systems approach by integrating PK/PD/TD and multi-omics. Therefore, the Specific Aims
of this application are: (1) To identify superior synergistic combinations of phage and polymyxin B, and evaluate
their PK/PD/TD against PDR K. pneumoniae using in vitro and animal infection models; (2) To elucidate the
mechanisms of synergistic bacterial killing by the superior phage-polymyxin combinations and the host-
pathogen-phage-polymyxin interactions using correlative multi-omics; and (3) To develop novel QSP models
integrating PK/PD/TD and multi-omics data for the superior phage-polymyxin combinations targeting PDR K.
pneumoniae, and propose optimal dosage regimens for future clinical trials. Our innovative multi-disciplinary
project will generate urgently needed information for rational optimization of novel phage-polymyxin
combinations. Importantly, this proposal aligns perfectly with the present NIAID RFA for exploiting phages to kill
‘superbugs’ and responds in a timely manner to the recent 2019 NIAID Antibiotic Resistance Framework to
protect global health security.
抗菌素耐药性(AMR)已成为全球对人类健康的最大威胁之一。潘杜鲁-
耐药(PDR)肺炎克雷伯菌已被世界卫生组织确定为全球三大肺炎克雷伯菌之一。
优先病原体迫切需要新的治疗方法。多粘菌素通常用作最后一种选择;然而,
质粒介导的多粘菌素耐药凸显了开发治疗PDR K的新疗法的紧迫性。
肺炎。噬菌体(即噬菌体)作为一种有希望的选择,最近引起了人们的极大关注
治疗PDR细菌感染;不幸的是,肺炎克雷伯菌对噬菌体单一疗法的抗药性可以迅速
发展。优化的噬菌体-抗生素组合提供了一种更好的方法;然而,有一个显著的不足
了解噬菌体疗法的pharmacokinetics/pharmacodynamics/toxicodynamics(PK/PD/TD)。这
这种情况严重阻碍了噬菌体疗法对细菌超级细菌的优化治疗,并限制了它们的
临床应用。传统的PK/PD/TD在优化抗生素给药方案中起着至关重要的作用,但缺乏
系统和机械信息。此外,抗生素PK/PD/TD不能容易地外推到噬菌体
治疗,主要是由于其独特的PK、宿主特异性和自我放大作用。作为噬菌体-抗生素的增效作用
取决于感染的动态和宿主的反应,结合系统的创新策略
药理学和宿主-病原体-噬菌体-抗生素的相互作用具有巨大的潜力来优化它们的
临床应用。令人兴奋的是,我们已经分离出了一些对肺炎克雷伯菌具有优异活性的噬菌体,
并确定了几种新的噬菌体-抗生素组合(例如与多粘菌素),它们可以协同杀死PDR K。
肺炎在体外和在没有任何再生的动物中。考虑到优化噬菌体疗法的迫切需要
为了减少对最后一株多粘菌素的抗性,培育优势噬菌体-多粘菌素是必不可少的
通过整合PK/PD/TD和多组学的系统方法进行组合。因此,具体目标是
本应用的目的是:(1)鉴定噬菌体和多粘菌素B的优良协同组合,并对其进行评价
用体外和动物感染模型研究其抗肺炎克雷伯菌的PK/PD/TD;(2)阐明
噬菌体-多粘菌素优势组合与寄主的协同杀菌机理
病原菌-噬菌体-多粘菌素相互作用的相关多组学研究;(3)发展新的QSP模型
整合PK/PD/TD和多组学数据,获得针对PDR K的优势噬菌体-多粘菌素组合。
肺炎,并为未来的临床试验提出最佳剂量方案。我们创新的多学科
该项目将产生合理优化新型噬菌体多粘菌素所急需的信息
组合。重要的是,这个提议与目前的NIAID RFA完全一致,因为它利用噬菌体来杀死
并及时对最近的2019年NIAID抗生素耐药性框架做出反应
保护全球卫生安全。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Comparative metabolomics revealed key pathways associated with the synergistic killing of multidrug-resistant Klebsiella pneumoniae by a bacteriophage-polymyxin combination.
比较代谢组学揭示了与通过噬菌体 - polymyxin组合通过协同杀死多药耐药性肺炎肺炎的关键途径。
- DOI:10.1016/j.csbj.2021.12.039
- 发表时间:2022
- 期刊:
- 影响因子:6
- 作者:Han ML;Nang SC;Lin YW;Zhu Y;Yu HH;Wickremasinghe H;Barlow CK;Creek DJ;Crawford S;Rao G;Dai C;Barr JJ;Chan K;Turner Schooley R;Velkov T;Li J
- 通讯作者:Li J
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jian Li其他文献
Jian Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jian Li', 18)}}的其他基金
Do long working hours increase the risk of cardiovascular disease mortality? Evidence from the U.S. National Health Interview Survey 1997-2015
长时间工作会增加心血管疾病死亡风险吗?
- 批准号:
10509317 - 财政年份:2023
- 资助金额:
$ 13.72万 - 项目类别:
Roles of heat shock transcriptional factor 1 in cell proliferation independent of the heat shock response
热休克转录因子 1 在细胞增殖中的作用与热休克反应无关
- 批准号:
10796280 - 财政年份:2020
- 资助金额:
$ 13.72万 - 项目类别:
Roles of heat shock transcriptional factor 1 in cell proliferation independent of the heat shock response
热休克转录因子 1 在细胞增殖中的作用与热休克反应无关
- 批准号:
10699046 - 财政年份:2020
- 资助金额:
$ 13.72万 - 项目类别:
Roles of heat shock transcriptional factor 1 in cell proliferation independent of the heat shock response
热休克转录因子 1 在细胞增殖中的作用与热休克反应无关
- 批准号:
10701882 - 财政年份:2020
- 资助金额:
$ 13.72万 - 项目类别:
Roles of heat shock transcriptional factor 1 in cell proliferation independent of the heat shock response
热休克转录因子 1 在细胞增殖中的作用与热休克反应无关
- 批准号:
10251924 - 财政年份:2020
- 资助金额:
$ 13.72万 - 项目类别:
Roles of heat shock transcriptional factor 1 in cell proliferation independent of the heat shock response
热休克转录因子 1 在细胞增殖中的作用与热休克反应无关
- 批准号:
10028798 - 财政年份:2020
- 资助金额:
$ 13.72万 - 项目类别:
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs
推进针对全耐药革兰氏阴性超级细菌的创新疗法
- 批准号:
10189507 - 财政年份:2019
- 资助金额:
$ 13.72万 - 项目类别:
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs
推进针对全耐药革兰氏阴性超级细菌的创新疗法
- 批准号:
10641847 - 财政年份:2019
- 资助金额:
$ 13.72万 - 项目类别:
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs
推进针对全耐药革兰氏阴性超级细菌的创新疗法
- 批准号:
10441316 - 财政年份:2019
- 资助金额:
$ 13.72万 - 项目类别:
Targeting the Urgent Need for New Antibiotics against Gram-negative ‘Superbugs’
针对针对革兰氏阴性“超级细菌”的新型抗生素的迫切需求
- 批准号:
10219081 - 财政年份:2017
- 资助金额:
$ 13.72万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 13.72万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 13.72万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 13.72万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 13.72万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 13.72万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 13.72万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 13.72万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 13.72万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 13.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 13.72万 - 项目类别:
Studentship